NCT06307015 De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)
| NCT ID | NCT06307015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal North Shore Hospital |
| Condition | HPV Positive Oropharyngeal Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2025-04-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective clinical trial is to determine if HPV-associated oropharyngeal squamous cell carcinoma that is non-hypoxic on FMISO PET can be successfully treated with a lower dose of radiation therapy. The main questions it aims to answer are: 1. What is the pathologic complete response rate in patients selected for radiation dose de-escalation and neck dissection? 2. What is the correlation between MRI and FMISO PET assessment of hypoxia before and during RT? 3. What are the acute and late toxicities in patients selected for radiation dose de-escalation? 4. What are the quality of life scores in patients selected for radiation dose de-escalation? 5. What are the local, regional and distant failure rates of patients selected for radiation dose de-escalation? Patients with cT1-2N1-2b (AJCC 7th edition) oropharyngeal tumours will undergo surgical resection of the primary tumour. Following this, they will be allocated to standard radiation therapy (70Gy with concurrent cisplatin chemotherapy) or de-escalation radiation therapy (30Gy with concurrent cisplatin chemotherapy) based on the results of FMISO PET. Patients with non-hypoxic tumours at baseline OR after two weeks of radiation therapy will be allocated to the de-escalated group. 3-4 months after completion of radiation therapy, all patients in the de-escalated group will undergo mandatory neck dissection to assess pathologic response. Researchers will assess the pathologic response rate after surgery in the de-escalation group. They will also compare the outcomes (oncological outcomes and quality of life) between the group receiving the standard treatment (70Gy) and the group receiving de-escalated radiation therapy (30Gy).
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Histologically confirmed cT1-2N1-2b oropharyngeal squamous cell carcinoma or cTxN1-2 carcinoma of unknown primary * p16 positive (70% nuclear and cytoplasmic staining) and HPV positive (genotyping via PCR) tumours of the tonsil, base of tongue, glossotonsillar sulcus, or unknown primary site (suspected mucosal origin). * No contraindications to radiotherapy, platinum-based chemotherapy or surgery * No contraindications to PET/CT or MRI * Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 (KPS \> 70%) * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study * Patients with a history of severe renal disease(s) (eGFR \<20) than cannot tolerate gadolinium chelate contrast agents.) * ECOG ≥ 3 * Previous high dose radiation therapy to the head or neck * Patients unwilling or unable to have PET/CT or MRI * Geographically remote patients unable to agree to imaging schedule * Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. * Patients with significant cardiac or pulmonary disease including cardiac arrythmias or Chronic Obstructive Pulmonary Disease (COPD) that are unable to tolerate high flow O2 for oxygen contrast. * Patients taking carbonic anhydrase inhibitors (acetazolamide) * History of glaucoma * Any implant, foreign body, 3T MRI incompatible device, or other contraindication to MRI imaging
Contact & Investigator
Anna Lawless
PRINCIPAL INVESTIGATOR
Royal North Shore Hospital
Frequently Asked Questions
Who can join the NCT06307015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HPV Positive Oropharyngeal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06307015 currently recruiting?
Yes, NCT06307015 is actively recruiting participants. Contact the research team at heidi.tsang@health.nsw.gov.au for enrollment information.
Where is the NCT06307015 trial being conducted?
This trial is being conducted at Saint Leonards, Australia.
Who is sponsoring the NCT06307015 clinical trial?
NCT06307015 is sponsored by Royal North Shore Hospital. The principal investigator is Anna Lawless at Royal North Shore Hospital. The trial plans to enroll 25 participants.